ES2314223T3 - Utilizacion de inhibidores de la tirosina quinasa para el tratamiento de trastornos por uso de sustancias. - Google Patents

Utilizacion de inhibidores de la tirosina quinasa para el tratamiento de trastornos por uso de sustancias. Download PDF

Info

Publication number
ES2314223T3
ES2314223T3 ES03743001T ES03743001T ES2314223T3 ES 2314223 T3 ES2314223 T3 ES 2314223T3 ES 03743001 T ES03743001 T ES 03743001T ES 03743001 T ES03743001 T ES 03743001T ES 2314223 T3 ES2314223 T3 ES 2314223T3
Authority
ES
Spain
Prior art keywords
drug
group
disorders
treatment
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03743001T
Other languages
English (en)
Spanish (es)
Inventor
Alain Moussy
Jean-Pierre Kinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Application granted granted Critical
Publication of ES2314223T3 publication Critical patent/ES2314223T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES03743001T 2002-02-27 2003-02-26 Utilizacion de inhibidores de la tirosina quinasa para el tratamiento de trastornos por uso de sustancias. Expired - Lifetime ES2314223T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35965102P 2002-02-27 2002-02-27
US359651P 2002-02-27

Publications (1)

Publication Number Publication Date
ES2314223T3 true ES2314223T3 (es) 2009-03-16

Family

ID=27766119

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03743001T Expired - Lifetime ES2314223T3 (es) 2002-02-27 2003-02-26 Utilizacion de inhibidores de la tirosina quinasa para el tratamiento de trastornos por uso de sustancias.

Country Status (9)

Country Link
US (1) US20050203098A1 (enExample)
EP (1) EP1490067B1 (enExample)
JP (1) JP2005530696A (enExample)
AT (1) ATE408407T1 (enExample)
AU (1) AU2003209933A1 (enExample)
CA (1) CA2477726A1 (enExample)
DE (1) DE60323613D1 (enExample)
ES (1) ES2314223T3 (enExample)
WO (1) WO2003072106A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030034171A (ko) 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DK1404331T3 (da) 2001-07-06 2008-01-28 Penwest Pharmaceuticals Co Sustained release-formuleringer af oxymorphon
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
HRP20110709T1 (hr) 2007-02-13 2011-11-30 Ab Science Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza
CN105974131B (zh) * 2016-06-16 2017-12-26 武汉大学 c‑Kit作为药物成瘾治疗靶点的应用
US20220079950A1 (en) * 2018-12-31 2022-03-17 The Regents Of The University Of California Therapeutic combinations as antidotes for organophosphate exposure
CN112575073B (zh) * 2019-09-30 2022-10-04 武汉大学 c-Kit作为成瘾诊断及监测标志物的应用
CN112569238A (zh) * 2019-09-30 2021-03-30 武汉大学 伊马替尼及其衍生物与镇痛药联合用药或复方制剂在治疗疼痛中的应用
US20240024325A1 (en) * 2020-08-28 2024-01-25 Emory University Methods of Managing Cocaine or Other Drug Addictions
CN114573591B (zh) * 2022-04-16 2023-04-25 成都施贝康生物医药科技有限公司 一种取代的吡咯并嘧啶化合物及其应用
CN117461602B (zh) * 2023-10-25 2024-10-25 六合熙诚(北京)信息科技有限公司 一种吗啡成瘾动物模型的构建方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (enExample) * 1992-04-03 1994-06-21 Ciba Geigy Ag

Also Published As

Publication number Publication date
WO2003072106A3 (en) 2004-04-22
DE60323613D1 (de) 2008-10-30
EP1490067A2 (en) 2004-12-29
US20050203098A1 (en) 2005-09-15
CA2477726A1 (en) 2003-09-04
WO2003072106A8 (en) 2004-10-07
WO2003072106A2 (en) 2003-09-04
JP2005530696A (ja) 2005-10-13
AU2003209933A1 (en) 2003-09-09
ATE408407T1 (de) 2008-10-15
EP1490067B1 (en) 2008-09-17

Similar Documents

Publication Publication Date Title
Criswell et al. Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats
Gebhart et al. Inhibition in spinal cord of nociceptive information by electrical stimulation and morphine microinjection at identical sites in midbrain of the cat
Kostrzewa et al. Proposed animal model of attention deficit hyperactivity disorder
Sonsalla et al. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Caballero-Florán et al. Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent
Qiu et al. Dexmedetomidine inhibits paraventricular corticotropin-releasing hormone neurons that attenuate acute stress-induced anxiety-like behavior in mice
Sun et al. Decrease of phosphorylated CREB and ERK in nucleus accumbens is associated with the incubation of heroin seeking induced by cues after withdrawal
Rezvani et al. Nicotine–alcohol interactions and cognitive function in rats
Buritova et al. Effects of nefopam on the spinal nociceptive processes: a c-Fos protein study in the rat
EP1490067B1 (en) Use of tyrosine kinase inhibitors for treating substance use disorders
Chen et al. Chronic nicotine exposure elicits pain hypersensitivity through activation of dopaminergic projections to anterior cingulate cortex
Yu et al. Pharmacological studies of 8-OH-DPAT-induced pupillary dilation in anesthetized rats
Zhang et al. Electroacupuncture alleviates affective pain in an inflammatory pain rat model
Khalili et al. Caffeine increases paragigantocellularis neuronal firing rate and induces withdrawal signs in morphine-dependent rats
Taksande et al. Acute orexigenic effect of agmatine involves interaction between central α2-adrenergic and GABAergic receptors
JP2008507577A (ja) 中枢神経系の障害を治療するための医薬
Cunha et al. Pentoxifylline improves learning and memory in glutamate-lesioned rats
RS67503A (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju psihotičnih poremećaja
De Gobbi et al. Activation of serotonergic 5-HT1A receptors in the lateral parabrachial nucleus increases NaCl intake
Trillat et al. Effects of WAY 100635 and (−)-5-Me-8-OH-DPAT, a novel 5-HT1A receptor antagonist, on 8-OH-DPAT responses
Zhang et al. Comprehensive perspectives for erectile dysfunction pharmacotherapy: from mechanism to application
ES2292794T3 (es) Compuestos para la supresion y/o alivio de la anhedonia.
Noseworthy Neurological therapeutics: principles and practice
Hawranko et al. Stress reduces morphine's antinociceptive potency: dependence upon spinal cholecystokinin processes
Comerma‐Steffensen et al. A novel reuptake inhibitor, IP2015, induces erection by increasing central dopamine and peripheral nitric oxide release